TEG subgroup analysis of the PRINCE trial demonstrated that ticagrelor was superior to clopidogrel in inhibiting platelet reactivity assessed by TEG among patients with acute minor stroke or TIA, particularly in carriers of the CYP2C19 LOF alleles. This evidence concerns the gene CYP2C19 and transient ischemic attack.